A Study to Evaluate the Efficacy of Bortezomib as Add on to a Standard Regimen of Intravenous Methylprednisolone (IVMP), Intravenous Immunoglobulins (IVIG) and Therapeutic Plasmapheresis (PLEX) in Patients with Biopsy Proven Antibody Mediated Rejection (ABMR) Following Renal Transplant

Trial Profile

A Study to Evaluate the Efficacy of Bortezomib as Add on to a Standard Regimen of Intravenous Methylprednisolone (IVMP), Intravenous Immunoglobulins (IVIG) and Therapeutic Plasmapheresis (PLEX) in Patients with Biopsy Proven Antibody Mediated Rejection (ABMR) Following Renal Transplant

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Bortezomib (Primary) ; Immunoglobulins (Primary) ; Methylprednisolone (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top